Form 4: Acadia Pharmaceuticals Executive Brendan Teehan Reports Stock Transactions

EVP, COO, and Head of Commercial Brendan Teehan of Acadia Pharmaceuticals reports the vesting of restricted stock units and subsequent sale of shares to cover withholding taxes.

Summary

• Brendan Teehan, EVP, COO, and Head of Commercial at Acadia Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On May 1, 2024, 6,814 restricted stock units vested, each representing a contingent right to receive one share of Acadia's common stock.
• Also on May 1, 2024, 6,814 shares were disposed of.
• On May 2, 2024, Teehan sold 3,477 shares of common stock at a weighted average price of $16.94 per share, with prices ranging from $16.94 to $17.02.
• The sales were mandatory and intended to cover withholding taxes related to the vesting of the restricted stock units.
• Following these transactions, Teehan directly owns 42,133 shares of Acadia Pharmaceuticals common stock and 20,445 restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing reflects routine transactions related to executive compensation and tax obligations.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares by an executive, but the impact is likely minimal given the context of tax obligations.

Key Dates